Skip to main content

Carbimazole‐induced agranulocytosis: does antineutrophil cytoplasmic antibody have a role?

Buy Article:

$43.00 plus tax (Refund Policy)

Carbimazole is a drug that is widely used for hyperthyroid disorders, such as Graves' disease. Agranulocytosis is a rare idiosyncratic adverse reaction to the drug which is potentially fatal. This report describes a patient with a history of successfully treated pyoderma gangrenosum, who developed agranulocytosis 3 weeks after commencement of carbimazole for Graves' disease. It may give credence to the theory that implicates antineutrophil cytoplasmic antibodies in the pathogenesis of agranulocytosis induced by antithyroid drugs.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Graves' disease; agranulocytosis; antineutrophil cytoplasmic antibody; autoantibody; carbimazole; pyoderma gangrenosum

Document Type: Research Article

Affiliations: 1: Department of Medicine 2: Endocrine Centre and 3: Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, Victoria, Australia

Publication date: 01 April 2010

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more